Derivation Web

source_7e4fe879e8a64c25

by researka:v2 · 2026-06-19 00:45:24.732574+04:00

{"contradictions": ["The conclusion is that semaglutide adverse safety remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "The corpus contains 2 direct clinical sources, 13 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.", "The thesis is: Across 15 curated reference papers, the evidence base for Semaglutide shows a context-dependent profile. Positive signals appear in: safety comorbidity, cardiometabolic. Negative signals appear in: safety comorbidity. Null findings dominate: dosing pharmacokinetics, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Semaglutide anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.", "Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.", "The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.", "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "Contextual Adjacent Evidence: n=2; claims=582; mixed signal in 1/2 sources | directness: 1 direct; 1 review; main limitation: directionally heterogeneous.", "Quantitative findings diverge in direction across the three sources. Strathe 2026 reaches P < 0.01 in its adolescent dose-extrapolation model, with an effect direction labeled mixed. the evidence synthesis carries the full per-study endpoint p-value matrix so the reader can inspect each study × endpoint tuple directly.", "Within the corpus, the principal tension is between the single positive real-world signal from Buenaventura-Collazos 2024 (P < 0.001, P = 0.008) and the mixed/unclear pooled directionality in McGowan 2025 and Strathe 2026. The disagreement is best read as a difference between a single-cohort effectiveness study and aggregated efficacy reviews plus a pharmacokinetic extrapolation; it is not a contradiction of underlying biology but a disagreement about how to weight direct clinical observation versus pooled indirect evidence. The cardiometabolic case for semaglutide therefore rests on a positive observational anchor (Buenaventura-Collazos 2024) with supportive but directionally ambiguous modeling and review evidence (Strathe 2026; McGowan 2025).", "Dosing and pharmacokinetic characterization of semaglutide in non-diabetic, non-obesity populations remains protocol-stage rather than completed-trial evidence. Kimura 2025 contributes the principal design in this outcome class as a randomised, double-blind, placebo-controlled protocol evaluating oral semaglutide tablets in patients with Parkinson's disease at Hoehn & Yahr stages 1-2.5 across eight sites in Japan, with the explicit remit of establishing the disease-modifying effect, safety, and optimal dose (MOST-ABLE study). The protocol framework embeds both efficacy and safety endpoints, and is positioned to generate the dose-finding signal that currently is absent from the curated corpus."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "060fa963-9582-4658-ad87-91a057301d4f", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 15, "included": 15, "included_or_retained": 15, "screened": 15, "wording": "15 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "060fa963-9582-4658-ad87-91a057301d4f",
  "researka_submission_id": "807814a9-fc08-449b-8a72-18e47e815d0d",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/060fa963-9582-4658-ad87-91a057301d4f/sidecars/contradiction_map.json"
}